Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | PROSPER: Enzalutamide vs. placebo for nmCRPC

Bertrand Tombal • 1 Jun 2019
ASCO 2019
Genitourinary Cancer Prostate Cancer Enzalutamide

Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium, explains the findings of the PROSPER (NCT02003924) trial which investigated the safety and efficacy of enzalutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Bertrand Tombal

1:24
PSA limitations in prostate cancer: advancing treatment de-escalation with imaging biomarkers
Bertrand Tombal • 5 Dec 2023
2:54
Time for treatment de-escalation for mHSPC?
Bertrand Tombal • 5 Jan 2024
2:43
Optimizing PSA recurrence treatment
Bertrand Tombal • 5 Dec 2023
2:10
PSA rise factors & significance of doubling time
Bertrand Tombal • 5 Dec 2023

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals